SLN is Silence Therapeutics plc (Healthcare) — a non-dividend-paying stock. Trading at $14.79. Market cap: $919M.
Stock snapshot
| Price | $14.79 |
| Market cap | $919M |
| Sector | Healthcare |
| Exchange | NGM |
| Pays dividend | No |
About SLN
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Related non-dividend companies
Other non-dividend stocks investors research alongside SLN. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is SLN's current stock price?
SLN (Silence Therapeutics plc) is currently trading at $14.79.
Does SLN pay a dividend?
SLN (Silence Therapeutics plc) does not currently pay a regular dividend.
Track SLN in DiviDrip
Add SLN to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search SLN and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-04. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.